Phase II trial of ZD0473 as second-line therapy in mesothelioma

European Journal of Cancer

Volumn 38, Issue SUPPL. 8, 2002, Pages

  Giaccone, G ^a   O'Brien, M E R ^b,c   Byrne, M J ^d   Bard, M ^e   Kaukel, E ^f   Smit, B ^g  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c Kent Cancer Centre   (United Kingdom)

^d SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f Asklepios Klinik Harburg   (Germany)

^g STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Chemotherapy; Mesothelioma; Second line; ZD0473

Indexed keywords

ALKALOID; AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; ANTIEMETIC AGENT; CISPLATIN; DOXORUBICIN; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; MITOMYCIN C; NAVELBINE; PLATINUM DERIVATIVE; VINBLASTINE; AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM(II); AMMINEDICHLORO(2-METHYLPYRIDINE)PLATINUM(II); ANTINEOPLASTIC AGENT; PLATINUM COMPLEX;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER GROWTH; CANCER RELAPSE; CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; FEMALE; HUMAN; LEUKOPENIA; LIFE EXPECTANCY; MALAISE; MALE; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; OTOTOXICITY; PAIN; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; THORAX PAIN; THROMBOCYTOPENIA; VOMITING; WORLD HEALTH ORGANIZATION; CHEMICALLY INDUCED DISORDER; HEMATOLOGIC DISEASE; INTRAVENOUS DRUG ADMINISTRATION; MESOTHELIOMA; MIDDLE AGED; PLEURA TUMOR; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSPNEA; FEMALE; HEMATOLOGIC DISEASES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MESOTHELIOMA; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PLEURAL NEOPLASMS; TREATMENT OUTCOME;

EID: 0036980434     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(02)80018-1     Document Type: Article

References (25)

1. Jaklitsch MT, Grondin SC, Sugarbaker DJ. Treatment of malignant mesothelioma. World J Surg 2001, 25, 210-217.
2. Mossman BT, Kamp DW, Weitzman SA. Mechanisms of carcinogenesis and clinical features of asbestos-associated cancers. Cancer Invest 1996, 14, 466-480.
3. Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. Lancet 1995, 345, 535-539.
4. Boylan AM. Mesothelioma: new concepts in diagnosis and management. Curr Opin Pulm Med 2000, 6, 157-163.
5. Boutin C, Monnet I, Ruffle P, Astoul P. Malignant mesothelioma: clinical and therapeutic study. Rev Mal Respir 1999, 16, 1317-1326.
6. Lee YCG, Light RW, Musk AW. Management of malignant pleural mesothelioma: a critical review. Curr Opin Pulm Med 2000, 6, 267-274.
7. Ho L, Sugarbaker DJ, Skarin AT. Malignant pleural mesothelioma. Cancer Treat Res 2001, 105, 327-373.
8. Segers K, Kumar-Singh S, Weyler J, et al. Glutathione S-transferase expression in malignant mesothelioma and non-neoplastic mesothelium: an immunohistochemical study. J Cancer Res Clin Oncol 1996, 122, 619-624.
9. Krarup-Hansen A, Hansen HH. Chemotherapy in malignant mesothelioma: a review. Cancer Chemother Pharmacol 1991, 28, 319-330.
10. Kindler HL, Millard F, Herndon JE, Vogelzang NJ, Suzuki Y, Green MR. Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B. Lung Cancer 2001, 31, 311-317.
11. Alberts AS, Falkson G, Van Zyl L. Malignant pleural mesothelioma: phase II pilot study of ifosfamide and mesna. J Natl Cancer Inst 1988, 80, 698-700.
12. Steele JP, Shamash J, Evans MT, et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000, 18, 3912-3917.
13. Solheim OP, Saeter G, Finnanger AM, Stenwig AE. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 1992, 65, 956-960.
14. Ryan CW, Herndon J, Vogelzang NJ. A review of chemotherapy trials for malignant mesothelioma. Chest 1998, 113, 66S-73S.
15. Planting AS, Schellens JH, Goey SH, et al. Weekly high-dose cisplatin in malignant pleural mesothelioma. Ann Oncol 1994, 5, 373-374.
16. Middleton GW, Smith IE, O'Brien ME, et al. Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 1998, 9, 269-273.
17. Kelland LR, Barnard CDJ. AMD473. Drugs of the Future 1998, 23, 1062-1065.
18. Gore M, Atkinson RJ, Dirix L, et al. ZD0473 phase II monotherapy trial in second-line ovarian cancer. Eur J Cancer 2001, 37, S261 (abstr 967).
19. Schiller J, Bonomi P, Modiano M, et al. Activity of ZD0473 in small-cell lung cancer: an update in patients relapsing after one prior chemotherapy regimen. Eur J Cancer 2001, 37, S62 (abstr 219).
20. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma. A review. J Clin Oncol 1996, 14, 1007-1017.
21. Parra HS, Tixi L, Latteri F, et al. Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP). Cancer 2001, 92, 650-656.
22. Vogelzang NJ, Rusthoven J, Paoletti P, et al. Phase III single-blinded study of pemetrexed + cisplatin vs. cisplatin alone in chemonaive patients with malignant pleural mesothelioma. Proc Am Soc Clin Oncol 2002, 21, 2a (abstr 5).
23. Byrne MJ, Davidson JA, Musk AW, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999, 17, 25-30.
24. Fizazi K, Caliandro R, Soulie P, et al. Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institut Gustave Roussy experience with chemotherapy and chemo-immunotherapy in mesothelioma. Eur J Cancer 2000, 36, 1514-1521.
25. Steele JP, Shmash J, Evans MT, et al. Phase II trial of vinorelbine and oxaliplatin (VO) in malignant pleural mesothelioma (MPM). Proc Am Soc Clin Oncol 2001, 20, 335a (abstr 1335).